Krenning E P, Teunissen J J M, Valkema R, deHerder W W, deJong M, Kwekkeboom D J
Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
J Endocrinol Invest. 2005;28(11 Suppl International):146-50.
Peptide receptor radionuclide therapy (PRRT) holds great promise for the future regarding the treatment of various cancers. With the use of radiolabelled peptides, which bind with high affinity to their receptors on cancer cells, it is possible to target the cancer efficiently. In gastroenteropancreatic tumors, radiolabelled somatostatin analog therapy has proven to be effective. Dose-limiting organs are the bone marrow and the kidneys. With the currently used dose schemes and kidney protection, PRRT is relatively safe and serious side-effecs are rare. Which radiolabelled somatostatin analog can be regarded as the most effective therapy cannot be concluded from the available literature. Also, the development of therapy strategies with combinations of different radionuclides and or peptides is of interest as these strategies may provide an increase in therapeutic efficacy in the future.
肽受体放射性核素治疗（PRRT）在未来治疗各种癌症方面具有巨大潜力。通过使用与癌细胞上的受体具有高亲和力结合的放射性标记肽，可以有效地靶向癌症。在胃肠胰腺肿瘤中，放射性标记的生长抑素类似物治疗已被证明是有效的。剂量限制器官是骨髓和肾脏。按照目前使用的剂量方案并进行肾脏保护，PRRT相对安全，严重副作用很少见。从现有文献中无法得出哪种放射性标记的生长抑素类似物可被视为最有效的治疗方法。此外，开发不同放射性核素和/或肽组合的治疗策略也很有意义，因为这些策略未来可能会提高治疗效果。
